Asthma and cystic fibrosis are two respiratory diseases characterized by chronic inflammation, leading to remodelling of the airways. Macrolides are widely used antibiotics, with a peculiar anti-inflammatory effect. On the basis of the methodologies used by the Cochrane collaboration, this review discusses the evidence for their long-term use as anti-inflammatory agents in these two diseases. Three randomized-controlled trials (RCTs) were identified for both asthma and cystic fibrosis. A positive effect of macrolides on reducing eosinophil numbers and markers of eosinophilic inflammation was demonstrated in patients with asthma. Data on cystic fibrosis demonstrated an effect on lung function with an increase of 5.4% in forced vital capacity (FVC) in patients treated with macrolide vs. placebo, but without a significant effect on FEV1. Side-effects were rare, mild and reversible on withdrawal of treatment. Although preliminary data from small studies are promising, the role of macrolides in the treatment of these chronic disorders needs to be more firmly established with larger, well-designed trials, targeted to investigate major clinical outcomes.

Macrolides in the treatment of asthma and cystic fibrosis / G., Ferrara; Losi, Monica; F., Franco; L., Corbetta; Fabbri, Leonardo; Richeldi, Luca. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - STAMPA. - 99:(2005), pp. 1-10.

Macrolides in the treatment of asthma and cystic fibrosis

LOSI, Monica;FABBRI, Leonardo;RICHELDI, Luca
2005

Abstract

Asthma and cystic fibrosis are two respiratory diseases characterized by chronic inflammation, leading to remodelling of the airways. Macrolides are widely used antibiotics, with a peculiar anti-inflammatory effect. On the basis of the methodologies used by the Cochrane collaboration, this review discusses the evidence for their long-term use as anti-inflammatory agents in these two diseases. Three randomized-controlled trials (RCTs) were identified for both asthma and cystic fibrosis. A positive effect of macrolides on reducing eosinophil numbers and markers of eosinophilic inflammation was demonstrated in patients with asthma. Data on cystic fibrosis demonstrated an effect on lung function with an increase of 5.4% in forced vital capacity (FVC) in patients treated with macrolide vs. placebo, but without a significant effect on FEV1. Side-effects were rare, mild and reversible on withdrawal of treatment. Although preliminary data from small studies are promising, the role of macrolides in the treatment of these chronic disorders needs to be more firmly established with larger, well-designed trials, targeted to investigate major clinical outcomes.
99
1
10
Macrolides in the treatment of asthma and cystic fibrosis / G., Ferrara; Losi, Monica; F., Franco; L., Corbetta; Fabbri, Leonardo; Richeldi, Luca. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - STAMPA. - 99:(2005), pp. 1-10.
G., Ferrara; Losi, Monica; F., Franco; L., Corbetta; Fabbri, Leonardo; Richeldi, Luca
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/304624
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 20
social impact